View in EDS

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis.

Saved in:
Bibliographic Details
Title: Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis.
Authors: Garitaonaindia, Yago1 (AUTHOR), Khan, Shawez1 (AUTHOR), Friis, Rasmus2 (AUTHOR), Kjær, Søren3 (AUTHOR), Borch, Troels H1 (AUTHOR), Ruhlmann, Christina3 (AUTHOR), Guldbrandt, Louise M2 (AUTHOR), Luczak, Adam A4 (AUTHOR), Schmidt, Henrik2 (AUTHOR), Bastholt, Lars3 (AUTHOR)
Source: JNCI: Journal of the National Cancer Institute. Feb2026, Vol. 118 Issue 2, p261-268. 8p.
Database: Academic Search Ultimate
Description
ISSN:00278874
DOI:10.1093/jnci/djaf263